Program
retatrutide
Also written as “Retatrutide”, “LY3437943” and “Retatrutide (LY3437943)”.
Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Atherosclerosis · Non-alcoholic Fatty Liver Disease · Diabetes Mellitus, led by 2 companies.
Drug pageRetatrutide: every studyAll 33 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lillyits history only | 3210 open or running | phase 3since May 22, 2023 | Feb 13, 2019 | Nov 2026phase 3 · NCT06662383 |
| Hudson Biotech | 11 open or running | phase 2since Mar 8, 2026 | Mar 8, 2026 | Mar 14, 2027phase 2 · NCT07467447 |
- Named in Eli Lilly’s own pipeline as
Retatrutide
, phase 3, as of Oct 29, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Hudson Biotech only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jan 19, 2023Named retatrutideINNProposed as its International Nonproprietary Name in WHO's List 128 · before, LY3437943
- Mar 8, 2026First study: phase 2 study in ObesityFirst studyNCT07467447 · 300 planned · China
Ahead
- Mar 14, 2027Primary completion: phase 2 study in ObesityNCT07467447
TargetBeta
“Glucagon receptor agonist; Glucagon-like peptide 1 receptor agonist; Gastric inhibitory polypeptide receptor agonist”ChEMBL 37, by rule
Other programs on the same three targets
Studies
The one study Hudson Biotech leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07467447Obesity · China | 2 | Recruiting | Mar 14, 2027 | 300 |
How it is read
Names in the registry
- “Retatrutide”, 18 entries
- “LY3437943”, 14 entries
- “Retatrutide (LY3437943)”, 1 entry
- “[¹⁴C]-LY3437943”, 1 entry
Conditions, from the studies’ own filings
- Obesity, 14 studies
- Diabetes Mellitus, Type 2, 8 studies
- Atherosclerosis, 1 study
- Non-alcoholic Fatty Liver Disease, 1 study
- Diabetes Mellitus, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.